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SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and 
related documents* 
Section/item Item
No 
Description Page Number 
Administrative information  
Title 1 Descriptive title identifying the study design, population, 
interventions, and, if applicable, trial acronym 
1 
Trial registration 2a Trial identifier and registry name. If not yet registered, name of 
intended registry 
4 
2b All items from the World Health Organization Trial Registration Data 
Set 
 
Protocol version 3 Date and version identifier N/A 
Funding 4 Sources and types of financial, material, and other support 7 
Roles and 
responsibilities 
5a Names, affiliations, and roles of protocol contributors 1 
5b Name and contact information for the trial sponsor  
 5c Role of study sponsor and funders, if any, in study design; 
collection, management, analysis, and interpretation of data; writing 
of the report; and the decision to submit the report for publication, 
including whether they will have ultimate authority over any of these 
activities 
25, Figure 1 
 5d Composition, roles, and responsibilities of the coordinating centre, 
steering committee, endpoint adjudication committee, data 
management team, and other individuals or groups overseeing the 
trial, if applicable (see Item 21a for data monitoring committee) 
7,8,12, 13, 25, 28,  
29 
Introduction    
Background and 
rationale 
6a Description of research question and justification for undertaking 
the trial, including summary of relevant studies (published and 
unpublished) examining benefits and harms for each intervention 
5-7 
 6b Explanation for choice of comparators 6-7 
Objectives 7 Specific objectives or hypotheses 8-10 
 2 
Trial design 8 Description of trial design including type of trial (eg, parallel group, 
crossover, factorial, single group), allocation ratio, and framework 
(eg, superiority, equivalence, noninferiority, exploratory) 
8 
Methods: Participants, interventions, and outcomes  
Study setting 9 Description of study settings (eg, community clinic, academic 
hospital) and list of countries where data will be collected. 
Reference to where list of study sites can be obtained 
8 
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, 
eligibility criteria for study centres and individuals who will perform 
the interventions (eg, surgeons, psychotherapists) 
16.17 
Interventions 11a Interventions for each group with sufficient detail to allow 
replication, including how and when they will be administered 
11,12 
11b Criteria for discontinuing or modifying allocated interventions for a 
given trial participant (eg, drug dose change in response to harms, 
participant request, or improving/worsening disease) 
13, 15 
11c Strategies to improve adherence to intervention protocols, and any 
procedures for monitoring adherence (eg, drug tablet return, 
laboratory tests) 
14,15 
11d Relevant concomitant care and interventions that are permitted or 
prohibited during the trial 
16,17, 21 
Outcomes 12 Primary, secondary, and other outcomes, including the specific 
measurement variable (eg, systolic blood pressure), analysis metric 
(eg, change from baseline, final value, time to event), method of 
aggregation (eg, median, proportion), and time point for each 
outcome. Explanation of the clinical relevance of chosen efficacy 
and harm outcomes is strongly recommended 
9,10, 26-28 
Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins 
and washouts), assessments, and visits for participants. A 
schematic diagram is highly recommended (see Figure) 
15, Figure 2 
Sample size 14 Estimated number of participants needed to achieve study 
objectives and how it was determined, including clinical and 
statistical assumptions supporting any sample size calculations 
15,16 
Recruitment 15 Strategies for achieving adequate participant enrolment to reach 
target sample size 
18 
Methods: Assignment of interventions (for controlled trials)  
Allocation:    
 3 
Sequence 
generation 
16a Method of generating the allocation sequence (eg, computer-
generated random numbers), and list of any factors for stratification. 
To reduce predictability of a random sequence, details of any 
planned restriction (eg, blocking) should be provided in a separate 
document that is unavailable to those who enrol participants or 
assign interventions 
11,12 
Allocation 
concealment 
mechanism 
16b Mechanism of implementing the allocation sequence (eg, central 
telephone; sequentially numbered, opaque, sealed envelopes), 
describing any steps to conceal the sequence until interventions are 
assigned 
11,12 
Implementation 16c Who will generate the allocation sequence, who will enrol 
participants, and who will assign participants to interventions 
11,12 
Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial 
participants, care providers, outcome assessors, data analysts), 
and how 
12,13 
 17b If blinded, circumstances under which unblinding is permissible, and 
procedure for revealing a participant’s allocated intervention during 
the trial 
13 
Methods: Data collection, management, and analysis  
Data collection 
methods 
18a Plans for assessment and collection of outcome, baseline, and 
other trial data, including any related processes to promote data 
quality (eg, duplicate measurements, training of assessors) and a 
description of study instruments (eg, questionnaires, laboratory 
tests) along with their reliability and validity, if known. Reference to 
where data collection forms can be found, if not in the protocol 
21-24 
 18b Plans to promote participant retention and complete follow-up, 
including list of any outcome data to be collected for participants 
who discontinue or deviate from intervention protocols 
14,15 
Data management 19 Plans for data entry, coding, security, and storage, including any 
related processes to promote data quality (eg, double data entry; 
range checks for data values). Reference to where details of data 
management procedures can be found, if not in the protocol 
13 
Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. 
Reference to where other details of the statistical analysis plan can 
be found, if not in the protocol 
25-28 
 20b Methods for any additional analyses (eg, subgroup and adjusted 
analyses) 
25-28 
 20c Definition of analysis population relating to protocol non-adherence 
(eg, as randomised analysis), and any statistical methods to handle 
missing data (eg, multiple imputation) 
15,16 
 4 
Methods: Monitoring  
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its 
role and reporting structure; statement of whether it is independent 
from the sponsor and competing interests; and reference to where 
further details about its charter can be found, if not in the protocol. 
Alternatively, an explanation of why a DMC is not needed 
25, 28, Figure 1 
 21b Description of any interim analyses and stopping guidelines, 
including who will have access to these interim results and make 
the final decision to terminate the trial 
13 
Harms 22 Plans for collecting, assessing, reporting, and managing solicited 
and spontaneously reported adverse events and other unintended 
effects of trial interventions or trial conduct 
24,25 
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and 
whether the process will be independent from investigators and the 
sponsor 
 
Ethics and dissemination  
Research ethics 
approval 
24 Plans for seeking research ethics committee/institutional review 
board (REC/IRB) approval 
29,30 
Protocol 
amendments 
25 Plans for communicating important protocol modifications (eg, 
changes to eligibility criteria, outcomes, analyses) to relevant 
parties (eg, investigators, REC/IRBs, trial participants, trial 
registries, journals, regulators) 
25,26 
Consent or assent 26a Who will obtain informed consent or assent from potential trial 
participants or authorised surrogates, and how (see Item 32) 
19, 30 
 26b Additional consent provisions for collection and use of participant 
data and biological specimens in ancillary studies, if applicable 
 
Confidentiality 27 How personal information about potential and enrolled participants 
will be collected, shared, and maintained in order to protect 
confidentiality before, during, and after the trial 
 
Declaration of 
interests 
28 Financial and other competing interests for principal investigators 
for the overall trial and each study site 
28 
Access to data 29 Statement of who will have access to the final trial dataset, and 
disclosure of contractual agreements that limit such access for 
investigators 
 
Ancillary and post-
trial care 
30 Provisions, if any, for ancillary and post-trial care, and for 
compensation to those who suffer harm from trial participation 
 
 5 
Dissemination 
policy 
31a Plans for investigators and sponsor to communicate trial results to 
participants, healthcare professionals, the public, and other relevant 
groups (eg, via publication, reporting in results databases, or other 
data sharing arrangements), including any publication restrictions 
 
 31b Authorship eligibility guidelines and any intended use of 
professional writers 
 
 31c Plans, if any, for granting public access to the full protocol, 
participant-level dataset, and statistical code 
 
Appendices    
Informed consent 
materials 
32 Model consent form and other related documentation given to 
participants and authorised surrogates 
 
Biological 
specimens 
33 Plans for collection, laboratory evaluation, and storage of biological 
specimens for genetic or molecular analysis in the current trial and 
for future use in ancillary studies, if applicable 
 
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 
Explanation & Elaboration for important clarification on the items. Amendments to the 
protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT 
Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” 
license. 
 
